As Insmed Incorporated (INSM) Share Price Declined, Baker Bros Advisors LP Raised Its Holding

Insmed Incorporated (NASDAQ:INSM) LogoInvestors sentiment increased to 2.07 in Q2 2019. Its up 0.17, from 1.9 in 2019Q1. It is positive, as 15 investors sold INSM shares while 29 reduced holdings. 30 funds opened positions while 61 raised stakes. 117.60 million shares or 52.97% more from 76.88 million shares in 2019Q1 were reported. Northern Trust stated it has 0.01% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Td Asset Management holds 0% or 127,346 shares. Moreover, Weiss Multi has 0.02% invested in Insmed Incorporated (NASDAQ:INSM). Franklin Res has 297,100 shares for 0% of their portfolio. Metropolitan Life Insur New York invested in 0.01% or 25,015 shares. Rice Hall James And Associates Ltd Llc has 467,541 shares for 0.4% of their portfolio. Macroview Inv Management Ltd Llc has 153 shares for 0.01% of their portfolio. Smith Asset Management Group Inc Lp owns 0% invested in Insmed Incorporated (NASDAQ:INSM) for 2,310 shares. Legal And General Public Ltd Com reported 40,273 shares. Proshare Ltd Limited Liability Company holds 0.01% or 33,654 shares. Northwestern Mutual Wealth Management Company holds 0% or 250 shares in its portfolio. Morgan Stanley has 636,406 shares for 0% of their portfolio. Voya Mgmt Limited Com holds 538,040 shares. Federated Pa holds 0.02% or 249,177 shares. Amundi Pioneer Asset Mgmt has 0.65% invested in Insmed Incorporated (NASDAQ:INSM) for 31.03M shares.

Baker Bros Advisors Lp increased its stake in Insmed Incorporated (INSM) by 18.51% based on its latest 2019Q2 regulatory filing with the SEC. Baker Bros Advisors Lp bought 384,615 shares as the company’s stock declined 24.70% . The hedge fund held 2.46 million shares of the health care company at the end of 2019Q2, valued at $63.03 million, up from 2.08 million at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Insmed Incorporated for a number of months, seems to be bullish on the $1.69 billion market cap company. The stock decreased 0.58% or $0.11 during the last trading session, reaching $18.9. About 459,991 shares traded. Insmed Incorporated (NASDAQ:INSM) has declined 9.30% since September 13, 2018 and is downtrending. It has underperformed by 9.30% the S&P500.

Baker Bros Advisors Lp, which manages about $8.20B and $14.71B US Long portfolio, decreased its stake in Array Biopharma Inc. (NASDAQ:ARRY) by 993,722 shares to 2.85M shares, valued at $131.97 million in 2019Q2, according to the filing. It also reduced its holding in Uniqure N.V. (NASDAQ:QURE) by 87,300 shares in the quarter, leaving it with 517,700 shares, and cut its stake in Genomic Health Inc. (NASDAQ:GHDX).

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: which released: “Volatility 101: Should Insmed (NASDAQ:INSM) Shares Have Dropped 28%? – Yahoo Finance” on August 13, 2019, also with their article: “Here’s Why Insmed Fell Hard Today – Nasdaq” published on August 01, 2019, published: “What Did Insmed Incorporated’s (NASDAQ:INSM) CEO Take Home Last Year? – Yahoo Finance” on May 22, 2019. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: and their article: “Insmed closes stock offering – Seeking Alpha” published on June 27, 2019 as well as‘s news article titled: “Is Insmed Incorporated (INSM) A Good Stock To Buy? – Yahoo Finance” with publication date: June 11, 2019.

Insmed Incorporated (NASDAQ:INSM) Ratings Coverage

Among 2 analysts covering Insmed (NASDAQ:INSM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insmed has $43 highest and $3000 lowest target. $36.50’s average target is 93.12% above currents $18.9 stock price. Insmed had 3 analyst reports since March 26, 2019 according to SRatingsIntel. On Tuesday, March 26 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Insmed Incorporated (NASDAQ:INSM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.